PROCEPT BioRobotics Corporation $PRCT Stock Holdings Lessened by SG Americas Securities LLC

SG Americas Securities LLC reduced its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 60.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 33,716 shares of the company’s stock after selling 50,578 shares during the quarter. SG Americas Securities LLC’s holdings in PROCEPT BioRobotics were worth $843,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its stake in PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after buying an additional 746 shares during the period. Center for Financial Planning Inc. purchased a new position in shares of PROCEPT BioRobotics during the 4th quarter valued at $40,000. US Bancorp DE grew its holdings in shares of PROCEPT BioRobotics by 175.7% during the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after acquiring an additional 1,079 shares in the last quarter. Lazard Asset Management LLC increased its stake in shares of PROCEPT BioRobotics by 90.7% in the second quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock worth $98,000 after acquiring an additional 810 shares during the last quarter. Finally, Osaic Holdings Inc. increased its stake in shares of PROCEPT BioRobotics by 20.3% in the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after acquiring an additional 337 shares during the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PRCT has been the subject of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Tuesday, April 21st. Leerink Partners lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. Wall Street Zen raised PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Citigroup lowered PROCEPT BioRobotics to a “hold” rating in a report on Thursday. Finally, Evercore began coverage on PROCEPT BioRobotics in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $30.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $40.00.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ:PRCT opened at $21.03 on Monday. The stock has a market capitalization of $1.20 billion, a PE ratio of -11.55 and a beta of 0.87. PROCEPT BioRobotics Corporation has a 1 year low of $19.35 and a 1 year high of $62.17. The firm has a fifty day moving average price of $25.05 and a 200 day moving average price of $27.10. The company has a current ratio of 6.73, a quick ratio of 5.51 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The company had revenue of $83.13 million for the quarter, compared to the consensus estimate of $80.52 million. During the same quarter last year, the business earned ($0.45) earnings per share. PROCEPT BioRobotics’s quarterly revenue was up 20.1% on a year-over-year basis. Analysts expect that PROCEPT BioRobotics Corporation will post -1.53 EPS for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.